Clinical trials: High Risk Leukaemia
Leukemia
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
RATIONALE: Collecting and storing samples of bone marrow and blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896766
- Testing
- loss of heterozygosity analysis, microarray analysis, polymorphism analysis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Oncology Group
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00006373
- Testing
- etoposide, ifosfamide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS.
- Trial name
- NCT04402541
- Testing
- CB-5339
- Where
- 10 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Cleave Therapeutics, Inc.
Myelodysplastic Syndromes, Myeloid Leukemia, Acute
TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Single-arm, single-center phase II trial to evaluate the antileukemic activity and safety/tolerability of TMLI/cyclophosphamide and etoposide conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in…
- Trial name
- TMLI-MA (NCT06598969)
- Testing
- Total bone marrow and lymphoid irradiation/cyclophosphamide/etoposide
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Leukemia
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004905
- Testing
- filgrastim, recombinant interferon alfa, cyclophosphamide
- Where
- 3 sites in United States
- Sponsor
- Loyola University
Invasive Aspergillosis, Acute Leukemia
Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients
The aim of our prospective and multicentre diagnostic study is therefore to elucidate on the sensitivity and specificity rates of these serologic markers in combination with molecular tools (both an Aspergillus specific and a…
- Conditions
- Invasive Aspergillosis, Acute Leukemia, Biomarkers, Stem Cell Transplantation
- Trial name
- NCT01695512
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Heidelberg University
Cancer, Breast Cancer
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the…
- Conditions
- Cancer, Breast Cancer, Lung Cancer, Colon Cancer
- Trial name
- LIBERATE (NCT03702309)
- Where
- Canada
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
High Risk Acute Myeloid Leukemia
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.
- Trial name
- 301 (NCT01696084)
- Testing
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Where
- 43 sites in United States, Canada
- Volunteers
- 309 people
- Sponsor
- Jazz Pharmaceuticals
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
In this trial the investigators aim to evaluate safety and efficacy of combination Ivosidenib (AG-120) and nivolumab in the context of adult patients with Isocitrate dehydrogenase-1 (IDH1) mutated acute myeloid leukemias (AML) or…
- Trial name
- NCT04044209
- Testing
- AG-120, Nivolumab
- Where
- United States
- Sponsor
- Yale University
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
For the first 28 day cycle, all patients will be treated with single agent pacritinib at 200 mg twice daily. The investigators chose this starting dose based on the previous three phase I studies of pacritinib as a single agent…
- Conditions
- Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- NCT02564536
- Testing
- Pacritinib, Decitabine
- Sponsor
- Washington University School of Medicine
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for…
- Trial name
- NCT04264806
- Testing
- Azacitidine, Cusatuzumab
- Where
- 73 sites in Australia, Brazil and 9 more
- Sponsor
- Janssen Research & Development, LLC
Leukemia
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation
Pilot, multicentric, open-label, single-arm, phase I-II clinical trial to evaluate the safety and efficacy of a novel Umbilical Cord Blood Transplantation (UCBT) platform, that consists of a UCBT of the 80 fraction, followed by a…
- Trial name
- NCT02328885
- Testing
- DLI of the 20 fraction of the UCBT
- Where
- 5 sites in Spain
- Volunteers
- 17 people
- Sponsor
- Banc de Sang i Teixits
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma
This randomized clinical trial studies how well a high-intensity intervention parenting program works in improving learning and school functioning in Latino children with acute leukemia or lymphoblastic lymphoma.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoblastic Lymphoma, Acute Leukemia
- Trial name
- NCT03178617
- Testing
- Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Philadelphia-Negative ALL, High-Risk Cancer
Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
Despite recent therapeutic advancements, the outcome of young adults with Philadelphia-negative (Ph-neg) acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) remains unsatisfactory, especially in those patients…
- Trial name
- NCT04334993
- Testing
- Blinatumomab
- Where
- 4 sites in Israel
- Volunteers
- 110 people
- Sponsor
- Israeli Medical Association
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
This phase II trial studies how well sirolimus and azacitidine works in treating patients with high-risk myelodysplastic syndrome or recurrent acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT01869114
- Testing
- Sirolimus, Azacitidine
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myelogenous Leukemia
Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS
This is a single center, open label, random comparison phase 2b study. The primary objective of this study is, by random comparison, to assess the anti-leukemia effect of allogeneic, donor-derived natural killer (NK) cells…
- Trial name
- DNKI-4 (NCT02477787)
- Testing
- allogeneic, donor-derived NK cells
- Where
- South Korea
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS).
- Trial name
- NCT04278768
- Testing
- Emavusertib, Venetoclax
- Where
- 32 sites in United States, Czechia and 6 more
- Volunteers
- 366 people
- Sponsor
- Curis, Inc.